Close Menu

NEW YORK ─ Cleveland-based Canary Health Technologies and Delhi-based Divoc Laboratories on Sunday announced that they will collaborate in a clinical trial to develop a rapid breath test for the detection of COVID-19.

The handheld test, called ASU Detect CV19, uses exhaled volatile organic compounds (VOCs) in human breath as biomarkers of the coronavirus that causes COVID-19.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.